Statin trial aims to boost immune system against prostate cancer

NCT ID NCT05586360

Recruiting now Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether taking simvastatin, a common cholesterol drug, for 8 weeks before prostate surgery can improve the immune system's ability to fight prostate cancer. Half of the 36 men with localized prostate cancer will receive the drug, while the other half will receive standard care. The study looks at changes in immune cells within the prostate to see if the drug reduces cancer-friendly immune activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Simvastatin 40mg
What this could lead to: If it works, this could point toward a way to use a common cholesterol drug to help the immune system fight prostate cancer.
What could go wrong: This is a small, early-phase trial with only 36 men, so results may not apply to everyone. The drug may not change immune activity as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Emory University
NOT_YET_RECRUITING

Atlanta, Georgia, 30322, United States
Hollings Cancer Center at Medical University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.